| Literature DB >> 27489587 |
Saeed Mohammadi1, Seyed H Ghaffari2, Mojgan Shaiegan3, Mahin Nikogoftar Zarif3, Mohsen Nikbakht2, Kamran Alimoghaddam2, Ardeshir Ghavamzadeh2.
Abstract
BACKGROUND: Acute myeloid leukemia (AML) is an immunophenotypically heterogeneous malignant disease, in which CD34 positivity is associated with poor prognosis. Osteopontin (OPN) plays different roles in physiologic and pathologic conditions like: survival, metastasis and cell protection from cytotoxic and apoptotic stimuli. Due to anti-apoptotic effect of OPN in normal and malignant cells, silencing of OPN leads to elevation of sensitivity towards chemotherapeutic agents and attenuates cancer cells migration and invasion. Therefore, the aim of this study was to evaluate OPN roles in modulating curcumin-mediated growth inhibitory on leukemic stem cells (LSCs) colony forming potential and survival in AML cell lines and primary CD34+/CD38- bone marrow-derived AML cells.Entities:
Keywords: Colony forming potential; Curcumin; Leukemic stem cell; Osteopontin; SiRNA
Year: 2016 PMID: 27489587 PMCID: PMC4969556
Source DB: PubMed Journal: Int J Hematol Oncol Stem Cell Res ISSN: 2008-2207
Characteristic of patients
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|
| P1 | 35Y/M | M1 | 32% | BM | 46, XY [8] | Neg | 905 |
| P2 | 40Y/M | M0 | 38% | BM | 46, XY [20] | Neg | 1810 |
| P3 | 30Y/M | M1 | 43% | BM | 50, XY add (3) (p12), -5, +8, +21, +21, +marI [4]/51, XY, idem, +18, +marI [3]/50, XY, idem, +22 [2]/51, XY, idem, 22, marI [2]/52, xy, IDEM, +18, marI, +marII [4]/46, xy [5], 45, xx, -7 [49]/46, XX [1] | Neg | 701 |
| P4 | 50Y/F | M0 | 61% | BM | 45, XX, -7 [49]/46, XX [1] | Neg | 4302 |
| P5 | 40Y/M | M2 | 77% | BM | 45, XY, del (5) (q14;q34), der (15), t (15;17) (p11.1 ;q11.1), -17 [12]/46, XY [38] | Neg | 3066 |
| P6 | 28Y/M | M4 | 15% | BM | 45, XY, [20] | Neg | 780 |
| P7 | 38Y/M | M2 | 40% | BM | 45, XY, [20] | Neg | 7331 |
| P8 | 36Y/M | M2 | 45% | BM | 46, XY, t (6;9) (p23;q3), t (9;18) (q34;q21) [20] | Neg | 5080 |
| P9 | 49Y/M | M4 | 30% | BM | 46, XY, del (11q23) [10] | Neg | 28911 |
| P10 | 30Y/F | M2 | 43% | BM | 46, XX, [20] | Neg | 3532 |
P: Patient, Y: Year, M: Male, F: Female, FAB: French-American-British, BMC: Bone marrow cells, %CD34 in BMC: Percentage of CD34+ cells in bone marrow cells of AML patients before sorting, FLT3: Fms like tyrosine kinase, WT-1: Wilms Tumor-1
Nucleotide sequences of primers used for Real-time RT-PCR
|
|
|
|
|
|
|---|---|---|---|---|
| HPRT | NM_000194 | TGGACAGGACTGAACGTCTTG | CCAGCAGGTCAGCAAAGAATTTA | 111 |
| OPN | NM_001251830 | ACCCTTCCAAGTAAGTCCAACG | GGTGAGAATCATCAGTGTCATCTAC | 139 |
OPN: Osteopontin, HPRT: Hypoxanthine-guanine phosphoribosyl transferase
SiRNA sequence
|
|
|
|---|---|
| Sense (5’-3’) | GGAAUAUUACUGUGGGAAAdTdT |
| Antisense (5’-3’) | UUUCCCACAGUAAUAUUCCdTdT |
Figure 1Effects of curcumin with different concentration (0-100 µM) on cell viability. Anti-growth effect of curcumin was measured by MTT assay following 24-48h exposure to KG-1 (A) and U937 cell lines (B). Data are mean ± SD of three independent experiments. Statistical significance was defined at *p<0.05, **p<0.01 and ***p<0.001 compared to corresponding control.
Figure 2Results of 7AAD assay in KG-1 and U937 cell lines after 24-48h treatment with different concentration of curcumin (0-80 µM). (A): Flow cytometry histograms and (B) bar charts in KG-1 cell line. (C): Flow cytometry histograms and (D) bar charts in U937 cell line
Figure 3Effects of curcumin (40 µM) and siRNA (40 pM) on colony forming potential. Colony formation assay confirms great decrease in colony count by curcumin and siRNA in both cell lines. Values are given as mean ± SD of three independent experiments.
Figure 4Result of osteopontin gene transfection with siRNA (40 pM) and treatment with curcumin (40 µM) in KG-1 and U937 cell lines. (A): Viability was assessed by MTT after transfection in both cell lines. (B): Results of Real-time PCR after transfection with in both cell lines showed that osteopontin could preclude curcumin-induced apoptosis and has additive effect with siRNA. Data are mean ± S.D. of three similar experiments.
Figure 5Curcumin was effective against primary CD34+/CD38- AML cells. (A): Primary CD34+/CD38- cells isolated from BMMCs of 10 AML patients and subjected to flow cytometry to determine the purity of CD34+/CD38- cells. (B): MTT assay were performed for all isolated AML samples which treated with different concentrations of curcumin (0, 20, 40 and 80 μM) for 24h. (C): Effects of siRNA (40 pM) transfection and curcumin treatment on growth inhibitory were examined by MTT and (D): Colony assay. Result on OPN gene expression (E): was evaluated by Real-time PCR. Values are given as mean ± SD of three independent experiments.
Figure 6Effects of curcumin and siRNA on colony forming potential of primary CD34+/CD38- AML sample. Data are mean ± S.D. of three independent experiments. Statistical significance was defined at *p<0.05, **p<0.01 and ***p<0.001 compared to corresponding control